vs
STANDARD BIOTOOLS INC.（LAB）与Seer, Inc.（SEER）财务数据对比。点击上方公司名可切换其他公司
Seer, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.3倍（$4.2M vs $3.2M）。STANDARD BIOTOOLS INC.净利率更高（598.5% vs -380.7%，领先979.2%）。STANDARD BIOTOOLS INC.同比增速更快（262.0% vs 5.0%）。STANDARD BIOTOOLS INC.自由现金流更多（$-1.7M vs $-11.1M）。过去两年Seer, Inc.的营收复合增速更高（17.1% vs -73.4%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Seer, Inc.是一家总部位于美国加利福尼亚州雷德伍德城的生物技术企业，成立于2017年，专注于开发蛋白质组学研究领域的相关技术，目前在生物科研技术开发领域开展业务。
LAB vs SEER — 直观对比
营收规模更大
SEER
是对方的1.3倍
$3.2M
营收增速更快
LAB
高出257.0%
5.0%
净利率更高
LAB
高出979.2%
-380.7%
自由现金流更多
LAB
多$9.4M
$-11.1M
两年增速更快
SEER
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2M | $4.2M |
| 净利润 | $19.3M | $-16.0M |
| 毛利率 | 83.5% | 52.0% |
| 营业利润率 | -578.6% | -413.8% |
| 净利率 | 598.5% | -380.7% |
| 营收同比 | 262.0% | 5.0% |
| 净利润同比 | 156.6% | 26.4% |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSEER
| Q4 25 | $3.2M | $4.2M | ||
| Q3 25 | $19.6M | $4.1M | ||
| Q2 25 | $21.8M | $4.1M | ||
| Q1 25 | $40.8M | $4.2M | ||
| Q4 24 | $890.0K | $4.0M | ||
| Q3 24 | $22.1M | $4.0M | ||
| Q2 24 | $22.5M | $3.1M | ||
| Q1 24 | $45.5M | $3.1M |
净利润LABSEER
| Q4 25 | $19.3M | $-16.0M | ||
| Q3 25 | $-34.7M | $-18.2M | ||
| Q2 25 | $-33.5M | $-19.4M | ||
| Q1 25 | $-26.0M | $-19.9M | ||
| Q4 24 | $-34.1M | $-21.7M | ||
| Q3 24 | $-26.9M | $-21.3M | ||
| Q2 24 | $-45.7M | $-22.9M | ||
| Q1 24 | $-32.2M | $-20.7M |
毛利率LABSEER
| Q4 25 | 83.5% | 52.0% | ||
| Q3 25 | 48.5% | 51.2% | ||
| Q2 25 | 48.8% | 52.1% | ||
| Q1 25 | 48.4% | 49.0% | ||
| Q4 24 | -202.8% | 50.6% | ||
| Q3 24 | 54.9% | 48.1% | ||
| Q2 24 | 46.1% | 56.3% | ||
| Q1 24 | 53.1% | 44.4% |
营业利润率LABSEER
| Q4 25 | -578.6% | -413.8% | ||
| Q3 25 | -168.5% | -469.4% | ||
| Q2 25 | -118.1% | -506.8% | ||
| Q1 25 | -80.8% | -493.0% | ||
| Q4 24 | -1162.1% | -587.2% | ||
| Q3 24 | -120.9% | -603.3% | ||
| Q2 24 | -134.5% | -882.0% | ||
| Q1 24 | -132.2% | -821.7% |
净利率LABSEER
| Q4 25 | 598.5% | -380.7% | ||
| Q3 25 | -177.4% | -442.5% | ||
| Q2 25 | -153.7% | -479.5% | ||
| Q1 25 | -63.8% | -474.4% | ||
| Q4 24 | -3828.3% | -543.6% | ||
| Q3 24 | -122.0% | -529.0% | ||
| Q2 24 | -203.3% | -743.8% | ||
| Q1 24 | -70.6% | -674.5% |
每股收益（稀释后）LABSEER
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $-0.06 | — | ||
| Q3 24 | $-0.07 | $-0.35 | ||
| Q2 24 | $-0.12 | $-0.35 | ||
| Q1 24 | $-0.27 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.9M | $47.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $424.3M | $259.3M |
| 总资产 | $567.8M | $296.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSEER
| Q4 25 | $120.9M | $47.3M | ||
| Q3 25 | $129.4M | $45.0M | ||
| Q2 25 | $158.6M | $37.9M | ||
| Q1 25 | $150.9M | $52.4M | ||
| Q4 24 | $166.7M | $40.8M | ||
| Q3 24 | $210.6M | $37.6M | ||
| Q2 24 | $269.8M | $31.9M | ||
| Q1 24 | $287.1M | $54.4M |
总债务LABSEER
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $299.0K | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSEER
| Q4 25 | $424.3M | $259.3M | ||
| Q3 25 | $399.7M | $271.8M | ||
| Q2 25 | $424.5M | $288.3M | ||
| Q1 25 | $454.6M | $311.0M | ||
| Q4 24 | $471.7M | $327.6M | ||
| Q3 24 | $489.3M | $344.7M | ||
| Q2 24 | $510.3M | $364.7M | ||
| Q1 24 | $577.3M | $383.6M |
总资产LABSEER
| Q4 25 | $567.8M | $296.1M | ||
| Q3 25 | $539.6M | $308.6M | ||
| Q2 25 | $557.0M | $322.5M | ||
| Q1 25 | $579.6M | $347.3M | ||
| Q4 24 | $612.3M | $366.6M | ||
| Q3 24 | $681.5M | $383.4M | ||
| Q2 24 | $708.7M | $406.6M | ||
| Q1 24 | $777.7M | $422.0M |
负债/权益比LABSEER
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-10.8M |
| 自由现金流经营现金流 - 资本支出 | $-1.7M | $-11.1M |
| 自由现金流率自由现金流/营收 | -51.7% | -264.2% |
| 资本支出强度资本支出/营收 | 14.8% | 7.0% |
| 现金转化率经营现金流/净利润 | -0.06× | — |
| 过去12个月自由现金流最近4个季度 | $-82.6M | $-46.2M |
8季度趋势，按日历期对齐
经营现金流LABSEER
| Q4 25 | $-1.2M | $-10.8M | ||
| Q3 25 | $-22.2M | $-7.6M | ||
| Q2 25 | $-20.7M | $-14.7M | ||
| Q1 25 | $-30.3M | $-11.4M | ||
| Q4 24 | $-14.1M | $-11.5M | ||
| Q3 24 | $-27.9M | $-14.1M | ||
| Q2 24 | $-39.0M | $-10.1M | ||
| Q1 24 | $-62.5M | $-10.5M |
自由现金流LABSEER
| Q4 25 | $-1.7M | $-11.1M | ||
| Q3 25 | $-23.1M | $-7.8M | ||
| Q2 25 | $-22.6M | $-15.2M | ||
| Q1 25 | $-35.3M | $-12.1M | ||
| Q4 24 | $-17.4M | $-12.0M | ||
| Q3 24 | $-30.1M | $-16.3M | ||
| Q2 24 | $-41.0M | $-11.2M | ||
| Q1 24 | $-63.3M | $-11.2M |
自由现金流率LABSEER
| Q4 25 | -51.7% | -264.2% | ||
| Q3 25 | -118.1% | -190.5% | ||
| Q2 25 | -103.6% | -375.9% | ||
| Q1 25 | -86.6% | -287.1% | ||
| Q4 24 | -1959.7% | -299.8% | ||
| Q3 24 | -136.4% | -404.7% | ||
| Q2 24 | -182.2% | -366.0% | ||
| Q1 24 | -138.9% | -365.6% |
资本支出强度LABSEER
| Q4 25 | 14.8% | 7.0% | ||
| Q3 25 | 4.5% | 6.9% | ||
| Q2 25 | 8.7% | 14.0% | ||
| Q1 25 | 12.4% | 15.6% | ||
| Q4 24 | 380.0% | 13.4% | ||
| Q3 24 | 10.2% | 54.4% | ||
| Q2 24 | 8.6% | 38.2% | ||
| Q1 24 | 1.7% | 24.6% |
现金转化率LABSEER
| Q4 25 | -0.06× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
